BETA DRUGS Financial Statement Analysis
|
||
|
The Revenues of BETA DRUGS have increased by 22.54% YoY .
The Earnings Per Share (EPS) of BETA DRUGS has increased by 10.87 % YoY. |
||
BETA DRUGS Last 5 Annual Financial Results
[NSE : BETA]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹362 Cr | ₹296 Cr | ₹227 Cr | ₹184 Cr | ₹116 Cr |
| Expenses | ₹288 Cr | ₹236 Cr | ₹174 Cr | ₹141 Cr | ₹91 Cr |
| Operating Profit (Excl OI) | ₹75 Cr | ₹60 Cr | ₹53 Cr | ₹43 Cr | ₹25 Cr |
| Other Income | ₹6.44 Cr | ₹1.36 Cr | ₹0.75 Cr | ₹0.76 Cr | ₹0.50 Cr |
| Interest | ₹6.99 Cr | ₹2.82 Cr | ₹2.42 Cr | ₹1.90 Cr | ₹2.42 Cr |
| Depreciation | ₹13 Cr | ₹9.78 Cr | ₹10 Cr | ₹7.25 Cr | ₹6.87 Cr |
| Profit Before Tax | ₹57 Cr | ₹49 Cr | ₹41 Cr | ₹34 Cr | ₹16 Cr |
| Profit After Tax | ₹42 Cr | ₹36 Cr | ₹31 Cr | ₹25 Cr | ₹12 Cr |
| Consolidated Net Profit | ₹42 Cr | ₹36 Cr | ₹31 Cr | ₹25 Cr | ₹12 Cr |
| Earnings Per Share (Rs) | ₹42.02 | ₹37.90 | ₹31.95 | ₹25.82 | ₹12.20 |
| PAT Margin (%) | 11.71 | 12.32 | 13.53 | 13.51 | 10.10 |
| ROE(%) | 23.95 | 26.03 | 28.55 | 30.85 | 18.65 |
| ROCE(%) | 25.23 | 32.74 | 33.94 | 36.38 | 22.17 |
| Total Debt/Equity(x) | 0.70 | 0.09 | 0.17 | 0.22 | 0.25 |
Key Financials |
||
| Market Cap | : | ₹ 2,558.6 Cr |
| Revenue (TTM) | : | ₹ 363.3 Cr |
| Net Profit(TTM) | : | ₹ 35.5 Cr |
| EPS (TTM) | : | ₹ 32.0 |
| P/E (TTM) | : | 72.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| BETA DRUGS | 5.2% | 25.6% | 30.3% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.7% | 8.1% | 16% |
| DIVIS LABORATORIES | 7% | 10.2% | 3.7% |
| TORRENT PHARMACEUTICALS | 2.5% | 11.3% | 49.6% |
| CIPLA | -0.3% | 4.1% | -3.3% |
| DR REDDYS LABORATORIES | -3.2% | -3.9% | -3% |
| MANKIND PHARMA | 0.6% | 7% | 4.1% |
| LUPIN | -0.4% | 9.6% | 28.5% |
| ZYDUS LIFESCIENCES | -0.5% | 6.1% | 15.3% |
BETA DRUGS Revenues
[NSE : BETA]
| Y-o-Y | 22.54 % |
| 5 Yr CAGR | 32.91 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹362 Cr | 22.54 | |
| Mar2024 | ₹296 Cr | 30.21 | |
| Mar2023 | ₹227 Cr | 23.54 | |
| Mar2022 | ₹184 Cr | 58.31 | |
| Mar2021 | ₹116 Cr | - | |
BETA DRUGS Operating Profit
[NSE : BETA]
| Y-o-Y | 24.35 % |
| 5 Yr CAGR | 31.77 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹75 Cr | 24.35 | |
| Mar2024 | ₹60 Cr | 12.93 | |
| Mar2023 | ₹53 Cr | 24.43 | |
| Mar2022 | ₹43 Cr | 72.57 | |
| Mar2021 | ₹25 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 1.48 % |
| 5 Yr CAGR | -0.86 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 20.59% | 1.48 | |
| Mar2024 | 20.29% | -13.25 | |
| Mar2023 | 23.39% | 0.69 | |
| Mar2022 | 23.23% | 9.01 | |
| Mar2021 | 21.31% | - | |
BETA DRUGS Profit After Tax
[NSE : BETA]
| Y-o-Y | 16.42 % |
| 5 Yr CAGR | 37.92 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹42 Cr | 16.42 | |
| Mar2024 | ₹36 Cr | 18.61 | |
| Mar2023 | ₹31 Cr | 23.73 | |
| Mar2022 | ₹25 Cr | 111.75 | |
| Mar2021 | ₹12 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -4.95 % |
| 5 Yr CAGR | 3.77 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 11.71 % | -4.95 | |
| Mar2024 | 12.32 % | -8.94 | |
| Mar2023 | 13.53 % | 0.15 | |
| Mar2022 | 13.51 % | 33.76 | |
| Mar2021 | 10.1 % | - | |
BETA DRUGS Earnings Per Share (EPS)
[NSE : BETA]
| Y-o-Y | 10.87 % |
| 5 Yr CAGR | 36.23 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹42 | 10.87 | |
| Mar2024 | ₹38 | 18.62 | |
| Mar2023 | ₹32 | 23.74 | |
| Mar2022 | ₹26 | 111.64 | |
| Mar2021 | ₹12 | - | |
BETA DRUGS Return on Capital Employed (ROCE)
[NSE : BETA]
| Y-o-Y | -22.94 % |
| 5 Yr CAGR | 3.29 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 25.23% | -22.94 | |
| Mar2024 | 32.74% | -3.54 | |
| Mar2023 | 33.94% | -6.71 | |
| Mar2022 | 36.38% | 64.10 | |
| Mar2021 | 22.17% | - | |
BETA DRUGS Share Price vs Sensex
| Current Share Price | : | ₹2,305.0 |
| Current MarketCap | : | ₹ 2,558.6 Cr |
| Updated EOD on | : | Jul 15,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BETA DRUGS | 5.2% |
25.6% |
30.3% |
| SENSEX | 0.9% |
2.2% |
-7.5% |
BETA DRUGS related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about BETA DRUGS Financials
How the annual revenues of BETA DRUGS have changed ?
The Revenues of BETA DRUGS have increased by 22.54% YoY .
How the Earnings per Share (EPS) of BETA DRUGS have changed?
The Earnings Per Share (EPS) of BETA DRUGS has increased by 10.87 % YoY .
Check out Intrinsic Value of Peers of BETA DRUGS
Compare Stock Analytics of Peers of BETA DRUGS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
